LILRB4 (BND-35 Biosimilar) Recombinant Monoclonal Antibody

1. Results suggest that ILT3 played an important role in tumor progression in colorectal cancer by possible influence on CD45RO+ T cells in the tumor microenvironment. PMID: 30126665
2. These results suggest that tyrosine phosphorylation may be critical in FcgammaRI-dependent endocytosis/phagocytosis that may be regulated by LILRB4 by triggering dephosphorylation of key signalling proteins. PMID: 27725776
3. ILT3 may functionally contribute to a regulatory network controlling tumor progression by suppressing the Akt pathway. PMID: 28931525
4. The ILT3 PBs/PCs were suggested to be developmentally equivalent based on the simultaneous generation of these populations upon activation of memory B cells in vitro ILT3 expression was found to be induced efficiently by IL-2, while IFN-alpha effectively induced ILT3 PBs/PCs in vitro Utilizing the elevated ILT3 will support opening a new avenue for molecular markers for, pathogenic cells. PMID: 27742834
5. this study shows that LILRB4 might have dual inhibitory and activating functions, depending on the position of the functional tyrosine residues in its immunoreceptor tyrosine-based inhibitory motifs and/or the nature of the stimuli PMID: 28409541
6. LILRB4 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
7. Identification of ILT4 as a cellular receptor for CSP C4d PMID: 26678451
8. ILT3Fc inhibits T cell activation and induces the generation of suppressor T cells targeting multiple inflammatory miRNA pathways. PMID: 22387553
9. Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance. PMID: 21454581
10. Data show that LILRB4 is a potent inhibitor of monocyte activation via FcgammaRI. PMID: 19833736
11. ILT3 precursor RNA is expressed and retained in nuclei of resting endothelial cells. PMID: 16433759
12. Our findings indicate that expression of ILT3 and ILT4 on CLL B cells represents a phenotypic abnormality that may play a role in tolerization of tumor-specific T cells. PMID: 17266150
13. The inhibitory effect of serum and membrane ILT3 in a humanized SCID mouse model describes an immune-escape mechanism that could contribute to impaired T cell responses in patients with cancer. PMID: 17513794
14. Both membrane and soluble ILT3 are proteins with potent immunosuppressive activity which are of importance for treatment of rejection, autoimmunity and cancer. PMID: 17923119
15. describe an immune-escape mechanism mediated by the inhibitory receptor immunoglobulin-like transcript 3 (ILT3) which may be responsible for failure of pancreatic cancer therapy PMID: 17993722
16. Progenitor mast cells expressed cell surface inhibitory LILRB4. Mature cord-blood-derived mast cells had detectable mRNA encoding multiple LILRs, none were expressed on the cell surface. PMID: 17998301
17. ILT3-Fc is a potent immunoregulatory agent that suppresses islet allograft rejection in humanized NOD/SCID mice. PMID: 18420485
18. 15 single nucleotide polymorphisms are identified in the extracellular domain of immunoglobulin-like transcript 3 gene from healthy individuals. PMID: 18486764
19. Expressed on cultured osteoclast precursor cells derived from peripheral blood monocytes; could be inhibitory for osteoclast development in presence of receptor activator of NF-kappaB ligand (RANKL) and macrophage colony stimulating factor (M-CSF). PMID: 18802077
20. A significant association is observed between ILT3 dendritic cells in kidney transplants and donor age. PMID: 19010139
21. ILT3 may play a critical role in the control of inflammation. PMID: 19380766
22. A tryptophan-deprived environment generates monocyte-derived dendritic cells with a marked up-regulation of inhibitory receptors ILT3 and ILT4 and enhanced capacity to induce CD4+CD25+Foxp3+ regulatory T cells in an ILT3-dependent manner. PMID: 19535644

Show More

Hide All

HGNC: 6608

OMIM: 604821

KEGG: hsa:11006

STRING: 9606.ENSP00000270452

UniGene: Hs.67846